01390nas a2200349   4500000000100000008004100001260001300042653001500055653001000070653000900080653002100089653001100110653002300121653001200144653001600156653002400172653001700196653002400213653001900237653001300256653001700269100002000286700001600306700001200322700001300334700001400347245009200361300001200453490000700465520055400472022001401026       1995                            d  c1995 Aug10aAdolescent10aAdult10aAged10aBiological Assay10aHumans10aLeprostatic Agents10aleprosy10aMiddle Aged10aMycobacterium bovis10aNerve Tissue10aOxidation-Reduction10aPalmitic Acids10aRifampin10aTibial Nerve1 aGuebre-Xabier M1 aShannon E J1 aKazen R1 aKebret Z1 aFrommel D00aEarly detection of rifampin in human nerve tissue after an oral dose of 600 milligrams.  a1866-700 v393 a<p>Rifampin in picogram quantities inhibited the ability of Mycobacterium bovis 44 BCG P3 to release 14CO2 from the oxidation of [14C]palmitic acid. By using these mycobacteria in a bioassay, samples of serum and posterior tibial nerve were assayed for inhibitory concentrations of rifampin. Within 8 to 12 h after ingestion of 600 mg of rifampin, the drug was detected in eight patients in concentrations ranging from 0.52 to 4.1 micrograms/ml in serum and in concentrations ranging from 0.6 to 6.3 ng/mg in posterior tibial nerve fiber tissue.</p>  a0066-4804